Stéphane Bancel, Moderna CEO (Joel Saget/AFP via Getty Images)
January 17, 2023 04:05 PM ESTUpdated January 17, 07:18 PM
R&D

Mod­er­na jumps in­to piv­otal pack with promis­ing RSV da­ta as big ri­vals face off in megablock­buster race

John Carroll

Editor & Founder

There’s a foot race de­vel­op­ing for the lead of a multi­bil­lion-dol­lar vac­cine mar­ket. And once again, Mod­er­na $MR­NA promis­es to be right in the thick …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times